Several comments in the MSAC application make me nervous.
"Summary of public consultation input Two organisations provided responses to the targeted consultation, the Endocrine Society of Australia (ESA) and the Royal College of Pathologists of Australasia (RCPA). Both organisations were not supportive of the application. RCPA considered that more supportive data may be required to support this application, including: the clinical utility of the three biomarkers, along with others (HDL, etc.), chosen to calculate the risk of developing kidney disease in diabetic patients the evidence behind the proposed frequency of testing, and the validity of the PromarkerD Hub, the software tool that contains a proprietary algorithm used to calculate the risk of developing, or further progression of DKD.
PIQ Price at posting:
96.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)